Valneva Aktie
| 4,49EUR | -0,04EUR | -0,88% |
WKN DE: A0MVJZ / ISIN: FR0004056851
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 676 | 713 | 674 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,23 | 0,24 | 0,26 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 586 | 425 | 263 | 299 | 223 |
| Summe Anlagevermögen | 240 | 208 | 207 | 211 | 176 |
| Summe Aktiva | 826 | 633 | 469 | 510 | 399 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 655 | 413 | 341 | 329 | 293 |
| Summe Eigenkapital | 171 | 220 | 128 | 181 | 106 |
| Summe Passiva | 826 | 633 | 469 | 510 | 399 |
Adresse
| Campus Bio-Ouest, 44800 Saint-Herblain | |
| Telefon | +33 (2) 28-07-37-10 |
| Internet | http://www.valneva.com |
Management
|
Anne-Marie Graffin
Chairman |
|
Danièle Guyot-Caparros
Director |
|
Dipal Patel
Chief Commercial Officer |
|
Gerd Zettlmeissl
Director |
|
Hanneke Schuitemaker
Chief Scientific Officer |
|
James Edward Connolly
Independent Director |
|
James R. Sulat
Vice Chairman |
|
Joshua Drumm
Vice President-Global Investor Relations |
|
Juan Carlos Jaramillo
Chief Medical Officer |
|
Kathrin U. Jansen
Director |
|
Kendra Wergin
Secretary & General Counsel |
|
Laetitia Bachelot-Fontaine
VP-Global Communications & European IR |
|
Maïlys Ferrère
Independent Director |
|
Peter Buhler
Chief Financial Officer |
|
Petra Pesendorfer
Chief People Officer |
|
Susanne Eder-Lingelbach
Vice President-Clinical Development |
|
Thomas Lingelbach
President, Chief Executive Officer & Director |
|
Vincent Dequenne
Chief Operating Officer |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.